Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher

Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a fresh disclosure attached to it.

Moderna stock is up 6% to $154 in morning trading, and the stock is up 137% over the past month. That extended rally traces back to the late-stage adjuvant melanoma readout reported in August, and the tape is still repricing off that single event for Moderna.

The sector backdrop isn’t providing the lift. The iShares Biotechnology ETF (NASDAQ:IBB) is up 1% to $204.5, a modest bid rather than a sector melt-up. Meanwhile, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is up 1% to $763.49, so the broad tape is essentially matching biotech’s pace and Moderna stock is doing this on its own.

Riding a Wave of Confidence

No Moderna announcement, filing, analyst action or trial result landed this morning to explain the move. What’s still driving the tape is the five-year Phase 2b adjuvant melanoma data presented at ASCO 2026, which showed intismeran autogene plus KEYTRUDA delivered a 49% reduction in risk of recurrence or death versus KEYTRUDA alone.

Merck (NYSE:MRK) is Moderna’s partner on that individualized neoantigen program, which now spans nine Phase 2/3 trials across melanoma, non-small cell lung cancer, bladder and renal cell carcinoma. Moderna’s chief development officer, David Berman, stated on the second-quarter call that “the data that we’ve shown at ASCO confirms that when we give the neoantigen vaccine, we do see neoantigen-specific T cells, and we know those T cells can kill the tumor.”

Moderna also guided to an interim analysis from its Phase 3 adjuvant melanoma trial in the second half of 2026, with management saying it is “highly confident” the interim will be conducted this year. That is the pipeline event the past-month move in Moderna is really underwriting.

What the Peer Tape Says

BioNTech (NASDAQ:BNTX) stock is up 1% to $97.00, a muted response given BioNTech runs its own individualized messenger RNA cancer vaccine program alongside Genentech. The gap matters here, because the closest peer using the same underlying technology is barely moving, which suggests the market is paying for Moderna’s specific asset rather than the messenger RNA cancer vaccine category as a whole.

Management at BioNTech has downplayed cross-read on the melanoma result. On the second-quarter call, chief medical officer Özlem Türeci stated that “in terms of biology and indication, we don’t see any Read through opportunities. Melanoma versus colorectal cancer, these are very different biologies and indications and responsiveness to immunotherapy and in particular antigen-specific T-cell antigens.” That framing from BioNTech helps explain why the stock isn’t running with Moderna today.

Also catching a sympathy bid, Novavax (NASDAQ:NVAX) stock is up 2% to $9.5 as a vaccine-sector name in the group. Novavax isn’t a participant in the messenger RNA cancer vaccine program described here, and its move today reads as group beta more than a discrete company catalyst.

Weighing the Cases on Moderna

The bull case for Moderna stock rests on optionality the market hasn’t yet seen data for. The adjuvant melanoma result is in hand, and the read across bladder, renal cell and lung has to be earned, not assumed, since checkpoint biology and neoantigen response can vary sharply across tumor types.

Moderna’s own outlook fits that framing. For 2026, the company guided to up to 10% revenue growth and year-end cash of $4.7 billion to $5.2 billion, numbers that fund the pipeline but don’t on their own justify the stock’s month. Chief executive Stéphane Bancel described oncology as a key focus for the second half of 2026, which puts more weight on the intismeran interim than on the base vaccine franchise for Moderna.

The complication is priced into that 137% one-month figure. A stock that has more than doubled in a month has priced a broad franchise off one indication, and the muted move in BioNTech is the tell that buyers are underwriting Moderna’s specific program rather than the platform. Until the full dataset arrives, Moderna stock is trading on a thesis rather than on a disclosure.

What to Watch

The full dataset from the August readout hasn’t yet been presented publicly, and the oncology congress in Madrid in late October is the next scheduled opportunity for it. Investors can watch for whether Moderna and Merck use that venue to release the underlying survival curves, subgroup detail and safety picture behind the headline number.

Ahead of that, the interim analysis from Moderna’s Phase 3 adjuvant melanoma trial is the swing factor for the next leg. Traders may want to check for whether Moderna issues that readout before Madrid, and whether management pairs it with accelerated-review language rather than waiting for the full analysis.

For position sizing on Moderna stock, a name that has traveled this fast in a month carries elevated give-back risk on any dataset that lands short of the setup that built the run. A cautious approach to fresh Moderna share exposure will keep one’s position small enough that a single conference slide can’t dictate the outcome for their portfolio.

Contact [email protected] for any questions or corrections.